Document is current
Any future updates will be listed below
-
Authors
Padilla-Padilla, Francisco G.
Ruiz-Bernes, Lina N.
Román-Pintos, Luis M.
Peraza-Zaldívar, Juan A.
Sander-Padilla, José G.
Lugo-Sánchez, Laura A.
Rios-Brito, Kevin F.
Arguedas-Núñez, María M.
Flores-Huanosta, Diana
González-Canudas, Jorge
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct0488229 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of the Fixed-Dose Combination of Atorvastatin/Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients with Type 2 Diabetes and Dyslipidemia
https://doi.org/10.1007/s40119-025-00410-y
-
Funding
Funding for this research was provided by:
Laboratorios Silanes SA de CV
- License Information
-
More Information
Article History
Received: 6 January 2025
Accepted: 1 April 2025
First Online: 5 May 2025
Declarations
:
: Francisco G. Padilla-Padilla, Lina N. Ruiz-Bernes, Luis M. Román-Pintos, Juan A. Peraza-Zaldívar, José G. Sander-Padilla, Laura A. Lugo-Sánchez, Kevin F. Rios-Brito, María M. Arguedas-Núñez, Diana Flores-Huanosta, and Jorge González-Canudas, have nothing to disclose.
: The study was developed following the legal provisions of the General Health Law of the United Mexican States and the Helsinki Declaration of 1964 and its later amendments. The study protocol, informed consent form (ICF), and any other relevant documents according to National Regulation were reviewed and approved by an independent ethics committee (IEC) (Investigación Biomédica para el Desarrollo de Fármacos, S.A. de C.V.), and by Mexican regulatory authorities (Federal Commission for the Protection against Sanitary Risks [COFEPRIS]), with authorization number COFEPRIS: 223300912X1745/2022 and registered in ClinicalTrials.gov No. NCT04882293.
